Table S1. Differential diagnosis identified among eligible patients.

| Diff diagnosis                                      | n  |
|-----------------------------------------------------|----|
| Atherosclerotic vascular disease                    | 6  |
| Calcinosis cutis                                    | 3  |
| Non uremic calciphylaxis                            | 2  |
| Pressure sore                                       | 2  |
| Pyoderma gangrenosum                                | 2  |
| Necrotizing vasculitis                              | 1  |
| Cholesterol embolization                            | 1  |
| Warfarin-induced skin necrosis                      | 1  |
| Cryoglobulinemia skin vasculitis                    | 1  |
| Ischemic steal syndrome related to arteriovenous fistula | 1  |
| Acute febrile neutrophilic dermatosis (Sweet syndrome) | 1  |
| Perforating ulcers                                  | 1  |
| Total                                               | 22 |
| Parameter                                                                 | N   | OR (95% CI)                     | p-value |
|---------------------------------------------------------------------------|-----|---------------------------------|---------|
| Age                                                                       | 210 | 1.25 (1.04-1.51)                | 0.02    |
| Gender                                                                    | 210 | 1.00 (0.05-18.91)               | 1.00    |
| BMI (per 5 kg/m$^2$ increase)                                             | 207 | 1.65 (1.30-2.09)                | <0.001  |
| BMI clusters (kg/m$^2$)                                                   | 207 |                                | <0.001  |
| Underweight vs Normal (18.5-25)                                           |      | 0.39 (0.08-2.01)                | 0.35    |
| Overweight (25-30) vs Normal (18.5-25)                                    |      | 1.03 (0.43-2.47)                | 0.87    |
| Obesity (30-40) vs Normal (18.5-25)                                      |      | 2.93 (1.23-6.96)                | 0.01    |
| Severe obesity (> 40) vs Normal (18.5-25)                                 |      | 12.78 (3.29-49.65)              | <0.001  |
| Loss of weight within 6 months before diagnosis                           | 200 | 1.45 (1.24-1.69)                | <0.001  |
| Diabetic and/or hypertension related nephropathy                          | 210 | 3.00 (1.64-5.47)                | <0.001  |
| Nephropathy                                                               | 210 |                                | 0.054   |
| Diabetes-associated nephropathy                                           |      | 6.90 (1.61-29.64)               | 0.01    |
| Hypertension-associated nephropathy                                       |      | 4.89 (1.18-20.27)               | 0.03    |
| Hypertension and diabetes-associated nephropathy                         |      | 3.25 (0.76-13.85)               | 0.11    |
| Glomerular nephropathy (diabetic excluded)                               |      | 1.54 (0.35-6.70)                | 0.56    |
| ADPKD                                                                     |      | 0.79 (0.11-5.48)                | 0.81    |
| Tubulo-interstitial nephropathy                                          |      | 1.75 (0.38-8.08)                | 0.47    |
| Other nephropathy                                                         |      | 1.16 (0.10-13.82)               | 0.91    |
| Multiple causes                                                           |      | 3.28 (0.65-16.64)               | 0.15    |
| History of PD                                                             | 210 | 1.78 (0.63-5.08)                | 0.28    |
| In-center dialysis                                                        | 207 | 2.12 (0.74-6.06)                | 0.16    |
| History of kidney graft                                                   | 210 | 0.54 (0.21-1.39)                | 0.20    |
| CAD                                                                       | 210 | 1.94 (1.04-3.62)                | 0.04    |
| Heart failure                                                             | 210 | 4.63 (2.32-9.26)                | <0.001  |
| Stroke                                                                    | 210 | 0.86 (0.39-1.86)                | 0.70    |
| PAD with symptoms                                                         | 210 | 1.95 (1.07-3.53)                | 0.03    |
| Diabetes mellitus                                                         | 210 | 2.71 (1.40-5.27)                | 0.003   |
| Arterial Hypertension                                                     | 210 | 3.47 (0.99-12.14)               | 0.05    |
| Hypercholesterolemia                                                      | 210 | 0.87 (0.49-1.54)                | 0.62    |
| Parathyroidectomy                                                         | 210 | 1.00 (0.30-3.32)                | 1.00    |
| History of pathologic fracture                                           | 210 | 2.41 (1.11-5.27)                | 0.03    |
| History of smoking                                                        | 207 | 1.23 (0.57-2.62)                | 0.60    |
| Progressive cancer                                                        | 210 | 1.00 (0.38-2.66)                | 1.00    |
| Hepatobiliary disease                                                     | 210 | 1.78 (0.79-3.98)                | 0.16    |
| Chronic alcoholism                                                        | 210 | 1.77 (0.50-6.24)                | 0.38    |
| Auto-immune disorder (connective tissue disease)                         | 210 | 2.00 (0.58-6.91)                | 0.27    |
| Thrombophilia                                                             | 210 | 1.25 (0.41-3.82)                | 0.70    |
| **At onset of lesions**                                                   |      |                                |         |
| Total serum calcium, per 0.5 mmol/L increment                             | 208 | 2.63 (1.12-6.15)                | 0.03    |
| Adjusted serum calcium, per 0.5 mmol/L increment                          | 206 | 9.16 (3.77-22.25)               | <0.001  |
| Serum phosphate, per 1 mmol/L increment                                   | 208 | 4.57(2.36-8.85)                 | <0.001  |
| Calcium phosphate product, per 1 mmol/L increase                          | 210 | 2.03 (1.52-2.73)                | <0.001  |
| Serum Albumin, per 5 g/L increment                                        | 206 | 0.82 (0.76-0.89)                | <0.001  |
| Serum Albumin variation between diagnosis and 6 months before, per 5 g/L increment | 202 | 0.40 (0.27-0.61)                | <0.001  |

Table S2. Univariate logistic regression analysis of risk factors of CUA in dialysis cases compared to matched dialysis controls.
| Metric                                                                 | Value   | p-Value   |
|------------------------------------------------------------------------|---------|-----------|
| iPTH (pg/mL)                                                           | 206     | 1.00 (1.00-1.00)    | 0.16    |
| Normalized iPTH, per 1 N increment                                      | 206     | 1.07 (1.01-1.12)    | 0.02    |
| iPTH outside of target range between 2 and 9 fold normal range         | 210     | 1.44 (0.79-2.62)    | 0.23    |
| 25-Hydroxyvitamin D (ng/mL)                                            | 156     | 1.00 (0.98-1.01)    | 0.63    |
| CRP, per 10 mg/L increment                                              | 205     | 1.37 (1.17-1.59)    | <0.001  |
| Hemoglobin, per 1 g/dL increment                                        | 206     | 0.72 (0.58-0.90)    | 0.005   |
| Hemoglobin A1c, per 1% increment                                        | 90      | 1.35 (0.82-2.22)    | 0.23    |

**Worst value within 6 months before onset of CUA**

| Metric                                                                 | Value   | p-Value   |
|------------------------------------------------------------------------|---------|-----------|
| Total serum calcium, per 0.5 mmol/L increment                           | 206     | 164.17 (0.07-383010.8) | 0.20    |
| Adjusted serum calcium, per 0.5 mmol/L increment                        | 203     | 2.15 (1.09-4.27)      | 0.03    |
| Serum phosphonate, per 1 mmol/L increment                               | 206     | 5.43 (2.58-11.41)     | <0.001  |
| Calcium phosphate product, per 1 mmol²/L² increment                     | 206     | 2.00 (1.48-2.70)      | <0.001  |
| Serum Albumin, per 5 g/L increment                                       | 203     | 0.94 (0.89-1.00)      | 0.05    |
| iPTH (pg/mL)                                                           | 193     | 1.00 (1.00-1.00)      | 0.08    |
| Normalized iPTH, per 1 N increment                                      | 193     | 1.06 (1.01-1.11)      | 0.01    |
| iPTH outside of target range between 2 and 9 fold normal range         | 210     | 2.02 (1.10-3.71)      | 0.02    |
| 25-Hydroxyvitamin D (ng/mL)                                            | 151     | 0.99 (0.97-1.01)      | 0.26    |
| CRP, per 10 mg/L increment                                              | 200     | 1.10 (1.03-1.16)      | 0.002   |

**Medication**

| Medication                                                                 | Value   | p-Value   |
|---------------------------------------------------------------------------|---------|-----------|
| 25-hydroxyvitamin D                                                       | 207     | 0.82 (0.44-1.51)    | 0.53    |
| Active vitamin D                                                          | 207     | 0.98 (0.48-2.00)    | 0.95    |
| Calcium-based phosphate binders                                           | 207     | 1.69 (0.97-2.93)    | 0.06    |
| Non calcium-based phosphate binders                                      | 207     | 1.36 (0.72-2.58)    | 0.34    |
| Sevelamer                                                                | 210     | 1.29 (0.70-2.36)    | 0.41    |
| Lanthanum carbonate                                                       | 210     | 1.18 (0.54-2.58)    | 0.68    |
| Cinacalcet                                                               | 206     | 1.23 (0.62-2.46)    | 0.55    |
| Betablocker                                                               | 207     | 1.39 (0.78-2.50)    | 0.27    |
| Insulin therapy                                                           | 208     | 2.12 (1.08-4.14)    | 0.03    |
| Vitamin K Antagonist                                                      | 208     | 8.42 (3.93-18.02)   | <0.001  |
| Corticosteroids                                                           | 208     | 1.00 (0.39-2.60)    | 1.00    |
| Statin                                                                    | 208     | 1.08 (0.60-1.94)    | 0.80    |
| ESA                                                                       | 207     | 2.56 (1.06-6.14)    | 0.04    |
| Iron therapy                                                              | 207     | 1.27 (0.62-2.61)    | 0.51    |
| ACEi/ARB                                                                  | 208     | 1.14 (0.62-2.10)    | 0.67    |
| Dialysis method: HD vs HDF                                                | 205     | 1.08 (0.55-2.12)    | 0.82    |
| eKt/V                                                                     | 193     | 0.18 (0.07-0.46)    | <0.001  |
| Citrate buffer                                                            | 210     | 1.00 (0.36-2.74)    | 1.00    |

ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; ADPKD, autosomal dominant polycystic kidney disease; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; CRP, C-reactive protein; CUA, calcific uremic arteriolopathy; ESA, erythropoiesis-stimulating agent; iPTH, intact parathyroid hormone; PAD, peripheral artery disease; PD, peritoneal dialysis.
Table S3. Univariate conditional logistic regression analysis of survival predictors among Calcific Uremic Arteriolopathy cases.

| Parameter                                           | N   | HR     | p-value |
|-----------------------------------------------------|-----|--------|---------|
| Age                                                 | 89  | 1.02   | 0.19    |
| Gender                                              | 89  | 0.91   | 0.73    |
| BMI (per 5 kg/m² increase)                          | 89  | 0.79   | 0.004   |
| BMI clusters (kg/m²)                                | 89  |        | 0.10    |
| Underweight vs Normal (18.5-25)                     |     | 0.78   | 0.18    |
| Overweight (25-30) vs Normal (18.5-25)              |     | 0.80   | 0.37    |
| Obesity (30-40) vs Normal (18.5-25)                 |     | 0.59   | 0.29    |
| Severe obesity (> 40) vs Normal (18.5-25)           |     | 0.25   | 0.09    |
| Loss of weight within 6 months before diagnosis     | 82  | 1.03   | 0.11    |
| Nephropathy                                         | 89  |        | 0.37    |
| Diabetes-associated nephropathy vs Unknown nephropathy |     | 2.47   | 0.24    |
| Hypertension-associated nephropathy                 |     | 1.91   | 0.43    |
| Hypertension and diabetes-associated nephropathy    |     | 3.89   | 0.08    |
| Glomerular nephropathy (diabetic excluded)          |     | 1.59   | 0.59    |
| ADPKD                                               |     | 2.39   | 0.39    |
| Tubulo-interstitial nephropathy                     |     | 1.88   | 0.48    |
| Other nephropathy                                   |     | 6.68   | 0.13    |
| Multiple causes                                     |     | 5.25   | 0.06    |
| History of PD                                       | 89  | 0.68   | 0.38    |
| In-center dialysis                                  | 67  | 1.48   | 0.52    |
| History of kidney graft                             | 89  | 0.57   | 0.29    |
| CAD                                                 | 89  | 1.01   | 0.96    |
| Heart failure                                       | 89  | 1.45   | 0.21    |
| Stroke                                              | 89  | 1.19   | 0.63    |
| PAD with symptoms                                   | 89  | 1.15   | 0.63    |
| Diabetes mellitus                                   | 89  | 1.24   | 0.47    |
| Arterial Hypertension                               | 89  | 0.93   | 0.88    |
| Hypercholesterolemia                                | 89  | 0.87   | 0.64    |
| Parathyroidectomy                                   | 89  | 0.39   | 0.36    |
| History of pathologic fracture                      | 89  | 0.89   | 0.73    |
| History of smoking                                  | 89  | 0.67   | 0.27    |
| Progressive cancer                                  | 89  | 1.19   | 0.69    |
| Hepatobiliary disease                               | 89  | 1.02   | 0.96    |
| Chronic alcoholism                                  | 89  | 0.55   | 0.26    |
| Auto-immune disorder (connective tissue disease)    | 89  | 0.56   | 0.42    |
| Thrombophilia                                       | 89  | 0.30   | 0.24    |
| At onset of lesions                                 |     |        |         |
| Total serum calcium, per 0.5 mmol/L increment       | 89  | 0.74   | 0.35    |
| Adjusted serum calcium, per 0.5 mmol/L increment    | 88  | 1.59   | 0.15    |
| Serum phosphate, per 1 mmol/L increment             | 89  | 0.82   | 0.34    |
| Calcium phosphate product, per 1 mmol2/L2 increment | 89  | 0.89   | 0.22    |
| Serum Albumin, per 5 g/L increment                  | 88  | 0.70   | <0.001  |
| Serum Albumin variation between diagnosis and 6 months before, per 5 g/L increment | 80  | 0.77   | 0.02    |
| iPTH (pg/mL)                                        | 87  | 1.00   | 0.69    |
| Variable                                                                 | n   | B (95% CI)      | p    |
|-------------------------------------------------------------------------|-----|----------------|------|
| Normalized iPTH, per 1 N increment                                      | 87  | 0.99 (0.95-1.03) | 0.71 |
| iPTH outside of target range between 2 and 9 fold normal range         | 89  | 0.83 (0.48-1.44) | 0.50 |
| 25-Hydroxyvitamin D (ng/mL)                                            | 68  | 0.99 (0.97-1.01) | 0.33 |
| CRP, per 10 mg/L increment                                              | 87  | 1.03 (0.99-1.07) | 0.12 |
| Hemoglobin, per 1 g/dL increment                                        | 89  | 0.85 (0.70-1.04) | 0.11 |
| Hemoglobin A1c, per 1% increment                                        | 54  | 1.30 (0.97-1.74) | 0.08 |
| **Worst value within 6 months before onset of CUA**                     |     |                 |      |
| Total serum calcium, per 0.5 mmol/L increment                           | 86  | 18.13 (0.03-9669) | 0.37 |
| Adjusted serum calcium, per 0.5 mmol/L increment                       | 82  | 1.68 (0.96-2.94) | 0.07 |
| Serum phosphate, per 1 mmol/L increment                                 | 86  | 0.82 (0.56-1.19) | 0.30 |
| Calcium phosphate product, per 1 mmol/L increment                       | 86  | 0.93 (0.80-1.07) | 0.30 |
| Serum Albumin, per 5 g/L increment                                      | 81  | 0.86 (0.68-1.10) | 0.22 |
| iPTH (pg/mL)                                                            | 75  | 1.00 (1.00-1.00) | 0.22 |
| Normalized iPTH, per 1 N increment                                      | 75  | 0.97 (0.94-1.01) | 0.17 |
| iPTH outside of target range between 2 and 9 fold normal range         | 89  | 0.82 (0.47-1.44) | 0.49 |
| 25-Hydroxyvitamin D (ng/mL)                                            | 59  | 1.00 (0.98-1.01) | 0.72 |
| CRP, per 10 mg/L increment                                              | 80  | 1.02 (0.98-1.06) | 0.30 |
| **Medication**                                                          |     |                 |      |
| 25-hydroxyvitamin D                                                     | 89  | 0.98 (0.55-1.72) | 0.94 |
| Active vitamin D                                                        | 89  | 0.72 (0.37-1.40) | 0.33 |
| Calcium-based phosphate binders                                        | 89  | 0.67 (0.38-1.17) | 0.16 |
| Non calcium-based phosphate binders                                    | 89  | 0.36 (0.20-0.64) | <0.001|
| Sevelamer                                                               | 89  | 0.61 (0.34-1.10) | 0.10 |
| Lanthanum carbonate                                                     | 89  | 0.25 (0.08-0.79) | 0.02 |
| Cinacalcet                                                             | 89  | 1.43 (0.72-2.81) | 0.31 |
| Betablocker                                                             | 89  | 0.76 (0.44-1.32) | 0.33 |
| Insulin therapy                                                         | 89  | 1.45 (0.82-2.56) | 0.20 |
| Vitamin K Antagonist                                                    | 89  | 0.90 (0.49-1.65) | 0.73 |
| Corticosteroids                                                         | 89  | 1.62 (0.72-3.64) | 0.24 |
| Statin                                                                  | 89  | 1.05 (0.60-1.84) | 0.87 |
| ESA                                                                     | 89  | 1.19 (0.58-2.45) | 0.64 |
| Iron therapy                                                            | 89  | 1.09 (0.59-2.03) | 0.79 |
| ACEi/ARB                                                                | 89  | 0.70 (0.39-1.27) | 0.24 |
| Dialysis method: HD vs HDF                                              | 67  | 1.16 (0.58-2.31) | 0.68 |
| eKt/V                                                                   | 62  | 1.00 (0.38-2.66) | 0.99 |
| Citrate buffer                                                          | 89  | 1.85 (0.77-4.42) | 0.17 |
| **Triggering event within the three months before onset**               |     |                 |      |
| Local triggering event                                                  | 28  |                 | 0.49 |
| Subcutaneous injection of heparin VS local trauma                       |     | 1.37 (0.37-5.05) | 0.64 |
| Insulin injection VS local trauma                                       |     | 0.69 (0.20-2.40) | 0.56 |
| Subcutaneous injection of heparin and insulin injection VS local trauma |     | 2.02 (0.35-11.7) | 0.43 |
| Hypovolemia                                                             | 89  | 1.36 (0.78-2.38) | 0.28 |
| Time between beginning of dialysis and onset of CUA                     | 70  | 1.00 (1.00-1.00) | 0.73 |
| Diagnosis delay, per 1 week increment                                   | 88  | 0.97 (0.95-1.00) | 0.054|
| **Localization**                                                        |     |                 |      |
| Lower limbs localization                                                | 89  | 1.48 (0.50-4.40) | 0.48 |
| Above knee VS none                                                      |     | 2.73 (0.92-8.16) | 0.07 |
| Description                                                                 | n  | HR   | 95% CI | p    |
|----------------------------------------------------------------------------|----|------|--------|------|
| Any localization VS none                                                  | 2.93 (0.93-9.27) | 0.07 |
| Trunk localization                                                        | 89 | 1.71 (0.51-5.71) | 0.39 |
| Gentiale localization VS none                                             | 1.54 (0.46-5.16) | 0.49 |
| Hip and buttock VS none                                                   | 1.31 (0.58-2.95) | 0.51 |
| Multiple trunk localization VS none                                       | 1.76 (0.89-3.45) | 0.10 |
| Upper limbs localization                                                  | 89 | 0.46 (0.14-1.52) | 0.46 |
| Below elbow VS none                                                       | 1.60 (0.63-4.11) | 0.32 |
| Any localization VS none                                                  | 1.76 (0.89-3.45) | 0.10 |
| Type of CUA                                                               | 89 | 1.30 (0.57-2.95) | 0.54 |
| Distal-type VS proximal-type                                              | 0.57 (0.29-1.15) | 0.12 |
| Proximal and distal type VS proximal type                                 | 1.42 (0.74-2.73) | 0.29 |
| Number of skin lesions                                                    | 89 | 1.03 (0.94-1.14) | 0.54 |
| Description of lesion                                                     |     |      |        |      |
| Reticulate purpura or livedo reticularis                                  | 89 | 0.45 (0.24-0.86) | 0.02 |
| Eschar                                                                    | 89 | 1.26 (0.50-3.21) | 0.63 |
| Violaceous plaque                                                         | 89 | 1.60 (0.89-2.88) | 0.11 |
| Ulceration                                                                | 89 | 1.12 (0.27-4.62) | 0.88 |
| Skin biopsy                                                               |     |      |        |      |
| Skin biopsy performed                                                     | 89 | 0.67 (0.37-1.22) | 0.19 |
| Number of skin biopsy performed                                           | 60 | 0.53 (0.29-0.95) | 0.03 |
| Skin biopsy performed by a surgeon                                        | 60 | 1.58 (0.66-3.74) | 0.30 |
| Histopathological findings                                                |     |      |        |      |
| Calcification in histopathological examination                            | 60 | 1.30 (0.57-2.95) | 0.54 |
| Arteriole VS none                                                         |     | 3.50 (1.11-11.0) | 0.03 |
| Extravascular VS none                                                     | 0.22 (0.03-1.78) | 0.16 |
| Thrombosis                                                                | 60 | 1.51 (0.76-3.01) | 0.24 |
| Intimal fibrosis                                                          | 60 | 0.72 (0.31-1.64) | 0.43 |
| Panniculitis                                                              | 60 | 0.69 (0.34-1.42) | 0.32 |
| Treatments                                                                |     |      |        |      |
| Intravenous STS                                                           | 89 | 0.69 (0.40-1.19) | 0.18 |
| STS cumulative dose (g)                                                    | 56 | 1.00 (0.98-1.02) | 0.78 |
| STS duration (week)                                                       | 58 | 0.88 (0.80-0.96) | 0.005 |
| Effective Intravenous STS *                                               |     |      |        |      |
| STS cumulative dose (g), per 100g increment                               | 51 | 0.87 (0.77-0.97) | 0.02 |
| STS duration (week)                                                       | 51 | 0.87 (0.77-0.97) | 0.02 |
| Cinacalcet                                                                | 89 | 1.33 (0.51-3.46) | 0.55 |
| Initiation or dose increase VS none                                       | 0.66 (0.36-1.21) | 0.18 |
| Continuation VS none                                                      | 89 | 0.38 (0.11-1.25) | 0.11 |
| Parathyroidectomy                                                         | 89 | 0.38 (0.11-1.25) | 0.11 |
| Sevelamer                                                                 | 89 | 0.49 (0.23-0.94) | 0.04 |
| Lanthanum carbonate                                                       | 89 | 0.64 (0.23-1.81) | 0.40 |
| Statin                                                                     | 89 | 0.26 (0.06-1.10) | 0.07 |
Initiation or dose increase VS none | 0.45 (0.13-1.50) |
Continuation VS none | 1.01 (0.56-1.80) |
Oxygen therapy : Standard oxygen therapy VS none | 0.83 (0.37-1.86) |
Surgical debridement | 0.66 (0.35-1.24) |
Amputation | 0.99 (0.50-1.97) |
Skin transplantation | 0.49 (0.17-1.41) |
Negative pressure wound therapy | 0.91 (0.41-2.02) |

**Renal Replacement Therapy modification**

| Increase of dialysis duration and/or frequency | 89 | 1.02 (0.58-1.81) |
Hemodialysis method | 86 | 0.56 |
Switch from HD to HDF VS no modification | 1.12 (0.43-2.90) |
Switch from HDF to HD VS non modification | 0.71 (0.36-1.40) |
Use of citrate dialysate | 89 | 1.72 (0.61-4.80) |
Nutritional support therapy | 89 | 1.46 (0.83-2.57) |
Antibiotherapy | 89 | 0.60 (0.32-1.13) |
Oral calcium supply | 53 | 0.23 |
Increase VS discontinuation | 1.23 (0.27-5.72) |
Lowering VS discontinuation | 0.71 (0.19-2.58) |
No modification VS discontinuation | 1.95 (0.90-4.23) |
Discontinuation of VKA | 65 | 0.41 (0.21-0.82) |
Discontinuation of iron therapy | 62 | 1.66 (0.68-4.03) |
Stereoids | 12 | 0.99 |
Discontinuation VS no modification | 0.87 (0.13-5.79) |
Dose decrease VS no modification | 1.11 (0.14-8.69) |
Initiation or dose increase VS no modification | 1.15 (0.16-8.38) |
Local steroids treatment | 89 | 0.95 (0.44-2.03) |
Discontinuation of native vitamin D | 52 | 1.24 (0.57-2.71) |
Discontinuation of active vitamin D | 20 | 2.14 (0.46-9.92) |
Local evolution of skin lesions | 89 | <0.001 |
Partial improvement VS complete healing | 1.32 (0.46-3.84) |
Deterioration VS complete healing | 11.45 (4.84-27.1) |
No improvement VS complete healing | 35.04 (6.51-189) |

Hazard ratio (HR) with 95% confidence interval. ACEi/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; ADPKD, autosomal dominant polycystic kidney disease; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; CRP, C-reactive protein; CUA, calcific uremic arteriolopathy; ESA, erythropoiesis-stimulating agent; HD, hemodialysis; HDF: hemodiafiltration; iPTH, intact parathyroid hormon; PAD, peripheral artery disease; PD, peritoneal dialysis; STS, sodium thiosulfate; VKA, vitamin K antagonist. *After removal of patients treated with intravenous STS for less than 2 weeks or with a cumulative dose of less than 150 g.